Avalo Therapeutics, Inc. (NASDAQ:AVTX) Short Interest Update

Avalo Therapeutics, Inc. (NASDAQ:AVTX) saw a significant growth in short interest in January. As of January 15th, there was short interest totalling 55,800 shares, a growth of 176.2% from the December 31st total of 20,200 shares. Currently, 0.7% of the shares of the stock are sold short. Based on an average daily volume of 96,900 shares, the days-to-cover ratio is currently 0.6 days.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on AVTX. BTIG Research assumed coverage on Avalo Therapeutics in a report on Thursday, December 19th. They issued a “buy” rating and a $40.00 target price for the company. HC Wainwright started coverage on shares of Avalo Therapeutics in a report on Thursday, October 24th. They set a “neutral” rating for the company.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Avalo Therapeutics stock. RA Capital Management L.P. bought a new position in Avalo Therapeutics, Inc. (NASDAQ:AVTX) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 967,000 shares of the company’s stock, valued at approximately $9,186,000. RA Capital Management L.P. owned about 93.88% of Avalo Therapeutics at the end of the most recent quarter. 87.06% of the stock is currently owned by institutional investors and hedge funds.

Avalo Therapeutics Trading Up 3.9 %

AVTX stock traded up $0.30 during midday trading on Thursday, reaching $7.90. 45,761 shares of the company’s stock traded hands, compared to its average volume of 84,603. The company has a 50-day simple moving average of $8.47 and a two-hundred day simple moving average of $9.84. Avalo Therapeutics has a 1-year low of $4.01 and a 1-year high of $34.46.

Avalo Therapeutics Company Profile

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.